Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276643 | 0.83 | RECQL (0.38) | CA2HTR6MTNR1AALDH1A1POLB | |
| SCHEMBL5212219 | 0.83 | RECQL (0.38) | CA2HTR6MTNR1AALDH1A1POLB | |
| SCHEMBL5212228 | 0.83 | RECQL (0.38) | CA2HTR6MTNR1AALDH1A1POLB | |
| SCHEMBL5211766 | 0.82 | HTR6 (0.41) | CA2HTR6ALDH1A1POLBFFAR1 | |
| SCHEMBL5746370 | 0.78 | SMN1; SMN2 (0.45) | ALDH1A1POLB | |
| SCHEMBL2798211 | 0.78 | TAAR1 (0.53) | CYP3A4 | |
| SCHEMBL5215763 | 0.77 | LMNA (0.39) | CA2HTR6ALDH1A1POLBDRD2 | |
| SCHEMBL1021657 | 0.76 | HTR6 (0.52) | CA2HTR6MTNR1AALDH1A1FFAR1 | |
| SCHEMBL1019478 | 0.76 | HTR6 (0.52) | CA2HTR6MTNR1AALDH1A1FFAR1 | |
| SCHEMBL1019674 | 0.76 | HTR6 (0.52) | CA2HTR6MTNR1AALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| EP-1554264-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037807-A9 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004037807-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205790-A1 | Medicinal arylethanolamine compounds | NAT1, AADAC, AHR | CA2 4006/4885HTR6 334/4885MTNR1A 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.